Dear Mary Zajakala:

The Center for Biologics Evaluation and Research (CBER) of the Food and Drug Administration (FDA) has completed its review of your premarket approval application (PMA) supplement for Alinity m HIV-1 assay to add claims for 1) use of the Alinity m HIV-1 assay as a supplemental test to confirm HIV-1 infection in individuals that have reactive results with HIV immunoassays in plasma, 2) use of serum as an additional specimen type for the supplemental claim, and 3) adding a new version of the Alinity m HIV-1 Application Specification File.

The Alinity m HIV-1 assay is an in vitro reverse transcription-polymerase chain reaction (RT-PCR) assay for the detection and quantification of Human Immunodeficiency Virus type 1 (HIV-1) RNA on the automated Alinity m System for confirmation of HIV-1 infection or for monitoring HIV-1 infected individuals. The Alinity m HIV-1 assay is intended for use in the clinical management of HIV-1 infected individuals in conjunction with clinical presentation and other laboratory markers.

The Alinity m HIV-1 assay is intended for use to monitor disease prognosis by measuring baseline plasma HIV-1 RNA level and to assess response to antiretroviral treatment by measuring changes in plasma HIV-1 RNA levels. Performance for quantitative monitoring is not established with serum specimens.

The Alinity m HIV-1 assay is also intended for use as a supplemental test to confirm HIV-1 infection in individuals who have reactive results with HIV immunoassays. Performance for supplemental use is established with both plasma and serum specimens.
The results from the Alinity m HIV-1 assay must be interpreted within the context of all relevant clinical and laboratory findings.

This device is not intended for use as a first line diagnostic test or for screening donors of blood, blood products, or human cells or tissues, or cellular and tissue-based products (HCT/Ps).

We are pleased to inform you that the PMA supplement is approved. You may begin commercial distribution of the device in accordance with the conditions of approval described below. Although this letter refers to your product as a device, please be aware that some approved products may instead be combination products. The Premarket Approval Database located at https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfPMA/pma.cfm identifies combination product submissions.

The sale and distribution of this device is restricted to prescription use in accordance with 21 CFR 801.109 and under section 515(d)(1)(B)(ii) of the Federal Food, Drug, and Cosmetic Act (the act). The device is further restricted under section 515(d)(1)(B)(ii) of the act insofar as the labeling must specify the specific training or experience practitioners need in order to use the device. FDA has determined that these restrictions on sale and distribution are necessary to provide reasonable assurance of the safety and effectiveness of the device. Your device is therefore a restricted device subject to the requirements in sections 502(q) and (r) of the act, in addition to the many other FDA requirements governing the manufacture, distribution, and marketing of devices.

Continued approval of the PMA is contingent upon the submission of periodic reports, required under 21 CFR 814.84, at intervals of one year (unless otherwise specified) from the date of approval of the original PMA. This report, identified as "Annual Report" and bearing the applicable PMA reference number, should be submitted to the address below. The Annual Report should indicate the beginning and ending date of the period covered by the report and should include the information required by 21 CFR 814.84.

In addition to the above, and in order to provide continued reasonable assurance of the safety and effectiveness of the PMA device, the Annual Report must include, separately for each model number (if applicable), the number of devices sold and distributed during the reporting period, including those distributed to distributors. The distribution data will serve as a denominator and provide necessary context for FDA to ascertain the frequency and prevalence of adverse events, as FDA evaluates the continued safety and effectiveness of the device.

This is a reminder that as of September 24, 2014, class III devices are subject to certain provisions of the final Unique Device Identification (UDI) rule. These provisions include the requirement to provide a UDI on the device label and packages (21 CFR 801.20), format dates on the device label in accordance with 21 CFR 801.18, and submit data to the Global Unique Device Identification Database (GUDID) (21 CFR 830 Subpart E). Additionally, 21 CFR 814.84 (b)(4) requires PMA annual reports submitted after
September 24, 2014, to identify each device identifier currently in use for the subject
device, and the device identifiers for devices that have been discontinued since the
previous periodic report. It is not necessary to identify any device identifier discontinued
prior to December 23, 2013. Combination Products may also be subject to UDI
requirements (see 21 CFR 801.30). For more information on these requirements,
please see the UDI website, https://www.fda.gov/medical-devices/device-advice-
comprehensive-regulatory-assistance/unique-device-identification-udi-system.

Before making any change affecting the safety or effectiveness of the PMA device, you
must submit a PMA supplement or an alternate submission (30-day notice) in
accordance with 21 CFR 814.39. All PMA supplements and alternate submissions (30-
day notice) must comply with the applicable requirements in 21 CFR 814.39. For more
information, please refer to the FDA guidance document entitled, "Modifications to
Devices Subject to Premarket Approval (PMA) - The PMA Supplement Decision-Making
Process" https://www.fda.gov/media/81431/download.

You are reminded that many FDA requirements govern the manufacture, distribution,
and marketing of devices. For example, in accordance with the Medical Device
Reporting (MDR) regulation, 21 CFR 803.50 and 21 CFR 803.52 for devices or
postmarketing safety reporting (21 CFR 4, Subpart B) for combination products, you are
required to report adverse events for this device. Manufacturers of medical devices,
including in vitro diagnostic devices, are required to report to FDA no later than 30
calendar days after the day they receive or otherwise becomes aware of information,
from any source, that reasonably suggests that one of their marketed devices:

1. May have caused or contributed to a death or serious injury; or

2. Has malfunctioned and such device or similar device marketed by the
manufacturer would be likely to cause or contribute to a death or serious injury if
the malfunction were to recur.

Additional information on MDR, including how, when, and where to report, is available at
https://www.fda.gov/medical-devices/medical-device-safety/medical-device-reporting-
mdr-how-report-medical-device-problems and on combination product postmarketing
safety reporting is available at (see https://www.fda.gov/combination-products/guidance-
regulatory-information/postmarketing-safety-reporting-combination-products).

In accordance with the recall requirements specified in 21 CFR 806.10 for devices or
the postmarketing safety reporting requirements (21 CFR 4, Subpart B) for combination
products, you are required to submit a written report to FDA of any correction or
removal of this device initiated by you to: (1) reduce a risk to health posed by the
device; or (2) remedy a violation of the act caused by the device which may present a
risk to health, with certain exceptions specified in 21 CFR 806.10(a)(2). Additional
information on recalls is available at
https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/industry-guidance-
recalls.
CBER does not evaluate information related to contract liability warranties. We remind you; however, that device labeling must be truthful and not misleading. CBER will notify the public of its decision to approve your PMA by making available, among other information, a summary of the safety and effectiveness data upon which the approval is based. The information can be found on the FDA CBER Internet Home Page located at https://www.fda.gov/vaccines-blood-biologics/approved-blood-products/premarket-approvals-and-humanitarian-device-exemptions-supporting-documents. Written requests for this information can also be made to the Food and Drug Administration, Dockets Management Branch, (HFA-305), 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852. The written request should include the PMA number or docket number. Within 30 days from the date that this information is placed on the Internet, any interested person may seek review of this decision by submitting a petition for review under section 515(g) of the act and requesting either a hearing or review by an independent advisory committee. FDA may, for good cause, extend this 30-day filing period.

Failure to comply with any post-approval requirement constitutes a ground for withdrawal of approval of a PMA. The introduction or delivery for introduction into interstate commerce of a device that is not in compliance with its conditions of approval is a violation of law.

You are reminded that, as soon as possible and before commercial distribution of your device, you must submit a Product Correspondence to this PMA submission with a copy of all final labeling. Final labeling that is identical to the labeling approved in draft form will not routinely be reviewed by FDA staff when accompanied by a cover letter stating that the final labeling is identical to the labeling approved in draft form. If the final labeling is not identical, any changes from the final draft labeling should be highlighted and explained in the Product Correspondence.

The CBER Document Control Center (DCC) will process paper and electronic media (CD/DVD, USB drive, etc.) submissions sent via U.S. mail or courier effective immediately.

All required documents should be submitted, unless otherwise specified, to the address below and should reference the above PMA number to facilitate processing.

Food and Drug Administration  
Center for Biologics Evaluation and Research  
Document Control Center  
10903 New Hampshire Ave.  
WO71-G112  
Silver Spring, MD 20993-0002
If you have any questions concerning the contents of the letter, please contact the Regulatory Project Manager, Dr. Vasantha Kumar, at (240) 402-8413 or Vasantha.Kumar@fda.hhs.gov.

Sincerely,

Hira L. Nakhasi, PhD
Director
Division of Emerging and
Transfusion Transmitted Diseases
Office of Blood Research and Review
Center for Biologics Evaluation and Research